Tesamorelin
Tesamorelin is a synthetic GHRH(1-44) analogue with an N-terminal trans-3-hexenoyl group that resists DPP-4 cleavage. Research compound.
1 vial · 10 mg total
Checking availability…
Total Price
฿1900
For research & laboratory use only. Not for human consumption.
Shipping: free within Thailand, ฿700 worldwide. Added at checkout. Delivery times & countries
Half-Life
~26-38 minutes
HIV Lipodystrophy
Approved for antiretroviral-induced lipodystrophy
DPP-IV Stabilised
Trans-3-hexenoic acid group on the N-terminus
Full-Length GHRH(1-44)
Complete sequence, unlike the GHRH(1-29) fragment sermorelin
Mechanism of Action
Scientific Research
J Acquir Immune Defic Syndr (2010)
J Clin Endocrinol Metab (2019)
N Engl J Med (2010)
Why Researchers Choose Tesamorelin
Tesamorelin is the only growth-hormone-releasing-hormone analogue to win FDA approval (as Egrifta), which makes it the most clinically validated GHRH peptide available for research. Its appeal is that it raises the body’s own pulsatile growth hormone rather than supplying exogenous GH, keeping the hormonal profile physiological and feedback-regulated. Common research uses include:
- Visceral adipose tissue (VAT) reduction and tissue-selective lipolysis studies
- Growth hormone and IGF-1 axis investigations using a pulsatile GHRH stimulus
- Lipid-profile and cardiovascular risk-marker research (triglycerides, carotid IMT)
- Age-related change in growth hormone secretion and IGF-1 expression
- Cognitive function studies in mild cognitive impairment
Clinical Validation
The tesamorelin Phase 3 programme ran two double-blind, randomised, placebo-controlled trials enrolling a combined total of more than 800 HIV-positive patients with lipodystrophy. The primary endpoint was visceral adipose tissue measured by CT scan, and the active arm achieved roughly 15 to 18 percent VAT reduction against placebo by 26 weeks, alongside meaningful improvements in lipid profiles and patient-reported outcomes. No other GHRH research peptide carries an evidence base of comparable depth.
Mechanism: Growth-Hormone-Driven Visceral Lipolysis
Tesamorelin triggers pulsatile growth hormone release by activating the GHRH receptor on pituitary somatotrophs. The released growth hormone then acts on visceral adipocytes through a defined cascade:
- Growth hormone binds the GH receptor and triggers JAK2-STAT5 signalling
- Hormone-sensitive lipase (HSL) is activated via the PKA pathway
- Lipolysis rises and free fatty acids are released
- Adipocyte sensitivity to insulin-stimulated lipogenesis declines
The published trials report tissue-specific differences in the measured endpoints between visceral and subcutaneous compartments.
Expanding Research: Cognition
A 2019 randomised trial (Baker et al., JCEM) reported that tesamorelin improved executive function, verbal memory, and overall cognitive composite scores in older adults with mild cognitive impairment (MCI). The authors proposed that GH and IGF-1 effects on neuronal metabolism and amyloid processing underlie the benefit, pointing to research applications well beyond the approved indication.
Reconstitution and Storage
Reconstitution: use bacteriostatic water; swirl gently until fully dissolved, do not shake. After reconstitution: store refrigerated and use within 30 days.
For research purposes only. Not for human consumption.
Ordering Tesamorelin in Thailand
Choose the required format from the options on this page and check current price and availability before ordering. For sourcing background, read our Tesamorelin Thailand guide.
For Bangkok, Phuket, Koh Samui and other Thai destinations, see how to order research peptides in Thailand. Enter a complete delivery address and a reachable Thai telephone number. Payment options are shown at checkout; processing and delivery estimates are explained in the shipping policy.
Vial & calculation
Calculate concentration and volume from the labelled amount, your final solution volume and a target amount you provide.
Open calculator for TesamorelinCurrent product variants are listed in the calculator. No personal dose is selected for you.
Product FAQs
Customer Reviews
very good product high-quality
can’t fault the service or responsiveness of the team. I’ve asked plenty of stupid questions, and they’re always polite, patient and incredibly helpful. Products are also delivered very quickly. Great service all round!
1mg before bed now and fat is melting away. Great price for this product, Milo, thank you!
Stacks Well With
Ipamorelin
Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHRP) that triggers clean, pulsatile GH release without spiking cortisol or prolactin.
CJC-1295 (no DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analogue that triggers pulsatile growth hormone release for muscle, recovery and fat-loss research.
Related Products
CJC-1295 (no DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analogue that triggers pulsatile growth hormone release for muscle, recovery and fat-loss research.
Ipamorelin
Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHRP) that triggers clean, pulsatile GH release without spiking cortisol or prolactin.
Sermorelin
Sermorelin (GRF 1-29) is a synthetic GHRH-analogue peptide that stimulates the pituitary to release growth hormone in natural, pulsatile rhythm.